Artelo Biosciences announced new research published in the peer-reviewed journal Pharmaceuticals. The research article, titled “Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration is Prevented via Cannabinoid Receptor 2 Agonism in Vitro,” highlights the promising protective properties of the Company’s clinical asset, ART27.13, in helping prevent muscle degeneration caused by cancer. Artelo is currently evaluating ART27.13, a dual CB1/CB2 receptor agonist, in the Cancer Appetite Recovery Study Phase 2a clinical trial to determine its effect on lean body mass, weight gain, activity levels, and improvement of anorexia in cancer patients. The purpose of this new research was to establish whether ART27.13 may additionally impact muscle degradation, a common debilitating effect of cancer and its treatment. Not only did the research show that ART27.13 protects against muscle wasting in the in vitro model, but also shows that the activity was mediated by the CB2 receptor.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARTL:
- Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
- Artelo Biosciences to present preclinical data on ART26.12
- Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
- H.C. Wainright healthcare analysts to hold an analyst/industry conference call
- Principal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia